Catalyst Pharmaceuticals Files 8-K
Ticker: CPRX · Form: 8-K · Filed: Jan 8, 2025 · CIK: 1369568
| Field | Detail |
|---|---|
| Company | Catalyst Pharmaceuticals, Inc. (CPRX) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, financial-statements
TL;DR
Catalyst Pharma filed a routine 8-K, mostly exhibits. No major news.
AI Summary
On January 8, 2025, Catalyst Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided text.
Why It Matters
This filing indicates Catalyst Pharmaceuticals is up-to-date with its regulatory reporting requirements, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard regulatory disclosure and does not contain information that suggests an immediate change in the company's risk profile.
Key Players & Entities
- CATALYST PHARMACEUTICALS, INC. (company) — Registrant
- January 8, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of incorporation
- 355 Alhambra Circle Suite 801 Coral Gables , Florida 33134 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Catalyst Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the filing's item information.
When was this 8-K report filed by Catalyst Pharmaceuticals, Inc.?
This 8-K report was filed on January 8, 2025.
In which state is Catalyst Pharmaceuticals, Inc. incorporated?
Catalyst Pharmaceuticals, Inc. is incorporated in Delaware.
What is the principal executive office address for Catalyst Pharmaceuticals, Inc.?
The principal executive office address is 355 Alhambra Circle Suite 801 Coral Gables, Florida 33134.
Does this filing report any specific material events or other significant business updates?
Based on the provided text, the filing primarily concerns financial statements and exhibits, and does not detail specific material events or other significant business updates.
Filing Stats: 628 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2025-01-08 16:43:18
Key Financial Figures
- $0.001 — Ticker Symbol Common Stock, par value $0.001 per share NASDAQ Capital Market CPR
Filing Documents
- d890025d8k.htm (8-K) — 26KB
- d890025dex991.htm (EX-99.1) — 7KB
- 0001193125-25-003549.txt ( ) — 160KB
- cprx-20250108.xsd (EX-101.SCH) — 3KB
- cprx-20250108_lab.xml (EX-101.LAB) — 18KB
- cprx-20250108_pre.xml (EX-101.PRE) — 11KB
- d890025d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Press release issued by the Company on January 8, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Catalyst Pharmaceuticals, Inc. By: /s/ Michael W. Kalb Michael W. Kalb Executive Vice President and Chief Financial Officer Dated: January 8, 2025 3